BRIEF-Transcode Therapeutics Announces Safety Review Committee Approval Of Opening Third Cohort And Preliminary Results From First Cohort In Phase 1 Ttx-Mc138 Trial

Reuters12-18 21:35

BRIEF-Transcode <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Safety Review Committee Approval Of Opening Third Cohort And Preliminary Results From First Cohort In Phase 1 Ttx-Mc138 Trial

Dec 18 (Reuters) - Transcode Therapeutics Inc RNAZ.O:

TRANSCODE THERAPEUTICS ANNOUNCES SAFETY REVIEW COMMITTEE APPROVAL OF OPENING THIRD COHORT AND PRELIMINARY RESULTS FROM FIRST COHORT IN PHASE 1 TTX-MC138 CLINICAL TRIAL
SAFETY REVIEW COMMITTEE APPROVES OPENING OF THIRD COHORT IN PHASE 1 TRIAL
NO SIGNIFICANT SAFETY OR DOSE LIMITING TOXICITIES REPORTED
TTX-MC138 SHOWS 66% INHIBITION OF MIR-10B AT 24 HOURS AFTER INFUSION

Source text: ID:nPn6sLSqWa

Further company coverage: RNAZ.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492859311?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-18 21:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492859311","market":"us","top_or_hot":-1,"title":"BRIEF-Transcode Therapeutics Announces Safety Review Committee Approval Of Opening Third Cohort And Preliminary Results From First Cohort In Phase 1 Ttx-Mc138 Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Transcode <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Safety Review Committee Approval Of Opening Third Cohort And Preliminary Results From First Cohort In Phase 1 Ttx-Mc138 Trial</title></head><body><p><span>Dec 18 (Reuters)</span><span> - </span>Transcode Therapeutics Inc <span>RNAZ.O</span>:</p><ul><li><p>TRANSCODE THERAPEUTICS ANNOUNCES SAFETY REVIEW COMMITTEE APPROVAL OF OPENING THIRD <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> AND PRELIMINARY RESULTS FROM FIRST COHORT IN PHASE 1 TTX-MC138 CLINICAL TRIAL</p></li><li><p>SAFETY REVIEW COMMITTEE APPROVES OPENING OF THIRD COHORT IN PHASE 1 TRIAL</p></li><li><p>NO SIGNIFICANT SAFETY OR DOSE LIMITING TOXICITIES REPORTED</p></li><li><p>TTX-MC138 SHOWS 66% INHIBITION OF MIR-10B AT 24 HOURS AFTER INFUSION</p></li></ul><p>Source text: <span>ID:nPn6sLSqWa</span></p><p>Further company coverage: <span>RNAZ.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Transcode Therapeutics Announces Safety Review Committee Approval Of Opening Third Cohort And Preliminary Results From First Cohort In Phase 1 Ttx-Mc138 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Transcode Therapeutics Announces Safety Review Committee Approval Of Opening Third Cohort And Preliminary Results From First Cohort In Phase 1 Ttx-Mc138 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-18 21:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUABKMC1N:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Transcode Therapeutics Announces Safety Review Committee Approval Of Opening Third Cohort And Preliminary Results From First Cohort In Phase 1 Ttx-Mc138 TrialDec 18 (Reuters) - Transcode ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUABKMC1N:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RNAZ","symbol_name":"TransCode Therapeutics  Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUABKMC1N:1","article_id":"2492859311","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492859311","pubTimestamp":1734528941,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Transcode Therapeutics Announces Safety Review Committee Approval Of Opening Third Cohort And Preliminary Results From First Cohort In Phase 1 Ttx-Mc138 TrialDec 18 (Reuters) - Transcode Therape","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RNAZ":"TransCode Therapeutics  Inc.","BK4139":"生物科技","BK4539":"次新股"},"translate_title":"BRIEF-Transcode Therapeutics宣布安全审查委员会批准开放第三个队列以及1期Ttx-Mc138试验第一个队列的初步结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNAZ":0.9},"content_text":"BRIEF-Transcode Therapeutics Announces Safety Review Committee Approval Of Opening Third Cohort And Preliminary Results From First Cohort In Phase 1 Ttx-Mc138 TrialDec 18 (Reuters) - Transcode Therapeutics Inc RNAZ.O:TRANSCODE THERAPEUTICS ANNOUNCES SAFETY REVIEW COMMITTEE APPROVAL OF OPENING THIRD COHORT AND PRELIMINARY RESULTS FROM FIRST COHORT IN PHASE 1 TTX-MC138 CLINICAL TRIALSAFETY REVIEW COMMITTEE APPROVES OPENING OF THIRD COHORT IN PHASE 1 TRIALNO SIGNIFICANT SAFETY OR DOSE LIMITING TOXICITIES REPORTEDTTX-MC138 SHOWS 66% INHIBITION OF MIR-10B AT 24 HOURS AFTER INFUSIONSource text: ID:nPn6sLSqWaFurther company coverage: RNAZ.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492859311"}